The GRM1 antibody targets the metabotropic glutamate receptor 1 (mGluR1), a G protein-coupled receptor encoded by the GRM1 gene. mGluR1 is predominantly expressed in the central nervous system, particularly in cerebellar Purkinje cells, hippocampus, and thalamus, where it regulates synaptic transmission, plasticity, and excitability by modulating intracellular signaling pathways (e.g., PLC and AC). Dysregulation of mGluR1 has been implicated in neurological disorders like spinocerebellar ataxia, epilepsy, autism spectrum disorders, and neurodegenerative conditions. In oncology, GRM1 overexpression is linked to melanoma progression and glioblastoma.
GRM1 antibodies are widely used in research to detect receptor expression, localization, and signaling dynamics via techniques such as Western blot, immunohistochemistry (IHC), and immunofluorescence (IF). They also aid in studying receptor-ligand interactions and downstream pathways. Therapeutically, GRM1-targeting monoclonal antibodies are under exploration for cancers with GRM1 dysregulation. For instance, preclinical studies show anti-GRM1 antibodies inhibit melanoma growth by blocking glutamate-mediated signaling. However, challenges remain in ensuring specificity and minimizing off-target effects in complex tissues.
Overall, GRM1 antibodies serve as critical tools for understanding neurological and oncological mechanisms, bridging basic research and potential clinical applications.